-
Je něco špatně v tomto záznamu ?
Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol
C. Rizzari, A. Möricke, MG. Valsecchi, V. Conter, M. Zimmermann, D. Silvestri, A. Attarbaschi, F. Niggli, D. Barbaric, J. Stary, S. Elitzur, G. Cario, L. Vinti, J. Boos, M. Zucchetti, C. Lanvers-Kaminsky, A. von Stackelberg, A. Biondi, M. Schrappe
Status neindexováno Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2017
PubMed Central
od 2017
Europe PubMed Central
od 2017
Wiley-Blackwell Open Access Titles
od 1997
- Publikační typ
- časopisecké články MeSH
The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR.
Cancer Centre for Children Sydney Children's Hospital Network Westmead NSW Australia
Department of Medicine and Surgery University of MIlano Bicocca Milano Italy
Department of Pediatric Hematology and Oncology Charité and Rudolf Virchow Hospital Berlin Germany
Department of Pediatric Hematology and Oncology University Childrens' Hospital of Münster Germany
Department of Pediatric Hematology Oncology Hannover Medical School Hannover Germany
Department of Pediatrics IRCCS San Gerardo dei Tintori Foundation Monza Italy
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23009639
- 003
- CZ-PrNML
- 005
- 20230721095520.0
- 007
- ta
- 008
- 230707s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/HS9.0000000000000893 $2 doi
- 035 __
- $a (PubMed)37275740
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Rizzari, Carmelo $u Department of Pediatrics, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy; Department of Medicine and Surgery, University of MIlano-Bicocca, Milano, Italy
- 245 10
- $a Incidence and Characteristics of Hypersensitivity Reactions to PEG-asparaginase Observed in 6136 Children With Acute Lymphoblastic Leukemia Enrolled in the AIEOP-BFM ALL 2009 Study Protocol / $c C. Rizzari, A. Möricke, MG. Valsecchi, V. Conter, M. Zimmermann, D. Silvestri, A. Attarbaschi, F. Niggli, D. Barbaric, J. Stary, S. Elitzur, G. Cario, L. Vinti, J. Boos, M. Zucchetti, C. Lanvers-Kaminsky, A. von Stackelberg, A. Biondi, M. Schrappe
- 520 9_
- $a The incidence of hypersensitivity reactions (HSRs) to PEG-asparaginase (PEG-ASNase) was evaluated in 6136 children with ALL enrolled in the AIEOP-BFM ALL 2009 study. Patients with B-cell precursor-acute lymphoblastic leukemia (BCP-ALL) were stratified as standard-risk/medium-risk (MR)/high-risk (HR) and those with T-ALL as non-High/HR. PEG-ASNase was administered intravenously at 2500 IU/sqm/dose. All patients received 2 PEG-ASNase doses in induction; thereafter non-HR versus HR patients received 1 versus 6 PEG-ASNase doses, respectively. After the single regular dose of PEG-ASNase at the beginning of delayed intensification, BCP-ALL-MR patients were randomized to receive 9 additional PEG-ASNase doses every 2 weeks (experimental arm [EA]) versus none (standard arm [SA]); HR patients were randomized to receive, in consolidation, 4 weekly PEG-ASNase doses (EA) versus none (SA). The HSR cumulative incidence (CI) was estimated adjusting for competing risks. An HSR occurred in 472 of 6136 (7.7%) patients. T-non- HR/BCP-Standard-Risk, BCP-MR-SA, BCP-MR-EA, HR-SA and HR-EA patients had 1-year-CI-HSR (±SE) rates of 5.2% (0.5), 5.2% (0.5), 4.0% (0.8), 20.2% (1.2), and 6.4% (1.3), respectively. The randomized intensification of PEG-ASNase did not significantly impact on HSR incidence in BCP-MR patients (1-y-CI-HSR 3.8% [0.8] versus 3.2% [0.6] in MR-EA versus MR-SA; P = 0.55), while impacted significantly in HR patients (1-y-CI-HSR 6.4% [1.3] versus 17.9% [1.8] in HR-EA and HR-SA, respectively; P < 0.001). The CI-HSR was comparable among non-HR groups and was not increased by a substantial intensification of PEG-ASNase in the BCP-MR-EA group whilst it was markedly higher in HR-SA than in HR-EA patients, suggesting that, in such a chemotherapy context, a continuous exposure to PEG-ASNase reduces the risk of developing an HSR.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Möricke, Anja $u Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Germany
- 700 1_
- $a Valsecchi, Maria Grazia $u Department of Pediatrics, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy; Department of Medicine and Surgery, University of MIlano-Bicocca, Milano, Italy $u Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy
- 700 1_
- $a Conter, Valentino $u Department of Pediatrics, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy; Department of Medicine and Surgery, University of MIlano-Bicocca, Milano, Italy
- 700 1_
- $a Zimmermann, Martin $u Department of Pediatric Hematology/Oncology, Hannover Medical School, Hannover, Germany
- 700 1_
- $a Silvestri, Daniela $u Department of Pediatrics, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy; Department of Medicine and Surgery, University of MIlano-Bicocca, Milano, Italy $u Bicocca Center of Bioinformatics, Biostatistics and Bioimaging, School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy
- 700 1_
- $a Attarbaschi, Andishe $u Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Medical University of Vienna, Austria $u St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria
- 700 1_
- $a Niggli, Felix $u University Children's Hospital, Zurich, Switzerland
- 700 1_
- $a Barbaric, Draga $u Cancer Centre for Children, Sydney Children's Hospital Network, Westmead, NSW, Australia
- 700 1_
- $a Stary, Jan $u Department of Pediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic
- 700 1_
- $a Elitzur, Sarah $u Pediatric Hematology-Oncology, Schneider Children's Medical Center, Petah Tikva, and Sackler Faculty of Medicine, Tel Aviv University, Petah Tikva, Israel
- 700 1_
- $a Cario, Gunnar $u Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Germany
- 700 1_
- $a Vinti, Luciana $u Department of Onco-Hematology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
- 700 1_
- $a Boos, Joachim $u Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Germany
- 700 1_
- $a Zucchetti, Massimo $u Department of Oncology Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Laboratory of Cancer Pharmacology, Milano, Italy
- 700 1_
- $a Lanvers-Kaminsky, Claudia $u Department of Pediatric Hematology and Oncology, University Childrens' Hospital of Münster, Germany
- 700 1_
- $a von Stackelberg, Arend $u Department of Pediatric Hematology and Oncology, Charité and Rudolf-Virchow-Hospital, Berlin, Germany
- 700 1_
- $a Biondi, Andrea $u Department of Pediatrics, IRCCS San Gerardo dei Tintori Foundation, Monza, Italy; Department of Medicine and Surgery, University of MIlano-Bicocca, Milano, Italy
- 700 1_
- $a Schrappe, Martin $u Department of Pediatrics I, Pediatric Hematology/Oncology, ALL-BFM Study Group, Christian Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, Germany
- 773 0_
- $w MED00201259 $t HemaSphere $x 2572-9241 $g Roč. 7, č. 6 (2023), s. e893
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37275740 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230707 $b ABA008
- 991 __
- $a 20230721095513 $b ABA008
- 999 __
- $a ok $b bmc $g 1958444 $s 1195903
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2023 $b 7 $c 6 $d e893 $e 20230601 $i 2572-9241 $m HemaSphere $n Hemasphere $x MED00201259
- LZP __
- $a Pubmed-20230707
